VANCOUVER, Dec. 11 /CNW/ - Inex Pharmaceuticals Corporation ("INEX";
TSX: IEX) today presented pre-clinical data confirming earlier studies that
its proprietary lead product candidate INX-0167 provides a strong immune
response that translates into a dramatic enhancement in the anti-tumor
activity of the monoclonal antibodies Rituxan(R) or Herceptin(R).
